About Metagenomi, Inc. Common Stock
https://www.metagenomi.coMetagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
CEO
Pamela M. Wapnick
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.24M
Value:$2.15M
SOZO VENTURES GP II, L.P.
Shares:581.58K
Value:$1.01M
CATALIO CAPITAL MANAGEMENT, LP
Shares:528.99K
Value:$915.16K
Summary
Showing Top 3 of 64
About Metagenomi, Inc. Common Stock
https://www.metagenomi.coMetagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.66M ▲ | $30.17M ▲ | $-20.39M ▼ | -235.51% ▼ | $-0.55 ▼ | $-19.3M ▲ |
| Q2-2025 | $8.51M ▲ | $6.99M ▼ | $-19.91M ▲ | -233.85% ▲ | $-0.54 ▲ | $-19.65M ▲ |
| Q1-2025 | $4.13M ▼ | $31.95M ▲ | $-25.04M ▼ | -606.71% ▼ | $-0.68 ▼ | $-26.46M ▼ |
| Q4-2024 | $9.61M ▼ | $30.24M ▼ | $-23.4M ▼ | -243.37% ▼ | $-0.63 ▼ | $-19.16M ▲ |
| Q3-2024 | $11.51M | $33.9M | $-18.77M | -163.04% | $-0.51 | $-21.02M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $184.11M ▼ | $247.94M ▼ | $69.49M ▼ | $178.45M ▼ |
| Q2-2025 | $204.99M ▼ | $272.28M ▼ | $76.45M ▼ | $195.83M ▼ |
| Q1-2025 | $225.97M ▼ | $297.87M ▼ | $85.21M ▼ | $212.66M ▼ |
| Q4-2024 | $248.31M ▼ | $324.6M ▼ | $89.74M ▼ | $234.86M ▼ |
| Q3-2024 | $274.59M | $358.35M | $102.58M | $255.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.39M ▼ | $-21.25M ▼ | $27.36M ▲ | $-187K ▼ | $5.92M ▲ | $-21.33M ▲ |
| Q2-2025 | $-19.91M ▲ | $-21.25M ▲ | $19.07M ▼ | $-166K ▼ | $-2.35M ▼ | $-21.38M ▲ |
| Q1-2025 | $-25.04M ▼ | $-22.84M ▲ | $24.73M ▼ | $-77K ▼ | $1.81M ▼ | $-23.13M ▲ |
| Q4-2024 | $-23.4M ▼ | $-26.28M ▲ | $28.55M ▲ | $0 ▲ | $2.27M ▲ | $-26.61M ▲ |
| Q3-2024 | $-18.77M | $-26.64M | $-8.93M | $-492K | $-36.06M | $-27.84M |
CEO
Pamela M. Wapnick
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.24M
Value:$2.15M
SOZO VENTURES GP II, L.P.
Shares:581.58K
Value:$1.01M
CATALIO CAPITAL MANAGEMENT, LP
Shares:528.99K
Value:$915.16K
Summary
Showing Top 3 of 64